EA201491914A1 - Способ лечения стероид-зависимых дерматозов - Google Patents

Способ лечения стероид-зависимых дерматозов

Info

Publication number
EA201491914A1
EA201491914A1 EA201491914A EA201491914A EA201491914A1 EA 201491914 A1 EA201491914 A1 EA 201491914A1 EA 201491914 A EA201491914 A EA 201491914A EA 201491914 A EA201491914 A EA 201491914A EA 201491914 A1 EA201491914 A1 EA 201491914A1
Authority
EA
Eurasian Patent Office
Prior art keywords
chloro
methyl
dependent
steroid
dermatosis
Prior art date
Application number
EA201491914A
Other languages
English (en)
Inventor
Панкадж Агарвал
Винод Кумар
Цин Се
Original Assignee
Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48143295&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201491914(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед filed Critical Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед
Publication of EA201491914A1 publication Critical patent/EA201491914A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Изобретен способ лечения стероид-зависимых дерматозов у млекопитающих, включая людей, нуждающихся в этом, который включает введение терапевтически эффективного количества соединения, выбираемого из группы, состоящей из N-{(1S)-2-амино-1-[(3-фторфенил)метил]этил}-5-хлор-4-(4-хлор-1-метил-1Н-пиразол-5-ил)-2-тиофенкарбоксамида или его фармацевтически приемлемой соли и соединения N-{(1S)-2-амино-1-[(3,4-дифторфенил)метил]этил}-5-хлор-4-(4-хлор-1-метил-1Н-пиразол-5-ил)-2-фуранкарбоксамида или его фармацевтически приемлемой соли, указанному млекопитающему.
EA201491914A 2012-04-24 2013-04-22 Способ лечения стероид-зависимых дерматозов EA201491914A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261637390P 2012-04-24 2012-04-24
US201361782565P 2013-03-14 2013-03-14
PCT/EP2013/058249 WO2013160222A1 (en) 2012-04-24 2013-04-22 Treatment method for steroid responsive dermatoses

Publications (1)

Publication Number Publication Date
EA201491914A1 true EA201491914A1 (ru) 2015-01-30

Family

ID=48143295

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491914A EA201491914A1 (ru) 2012-04-24 2013-04-22 Способ лечения стероид-зависимых дерматозов

Country Status (26)

Country Link
US (2) US20150087683A1 (ru)
EP (1) EP2841053A1 (ru)
JP (1) JP2015514792A (ru)
KR (1) KR20150010943A (ru)
CN (1) CN104302275A (ru)
AR (1) AR090795A1 (ru)
AU (1) AU2013254849B2 (ru)
BR (1) BR112014026706A2 (ru)
CA (1) CA2873751A1 (ru)
CL (1) CL2014002861A1 (ru)
CO (1) CO7111283A2 (ru)
CR (1) CR20140491A (ru)
DO (1) DOP2014000238A (ru)
EA (1) EA201491914A1 (ru)
HK (1) HK1201726A1 (ru)
IL (1) IL235159A0 (ru)
MX (1) MX2014012904A (ru)
NZ (1) NZ628394A (ru)
PE (1) PE20142356A1 (ru)
PH (1) PH12014502400A1 (ru)
SG (1) SG11201406409VA (ru)
TW (1) TW201347758A (ru)
UA (1) UA113875C2 (ru)
UY (1) UY34762A (ru)
WO (1) WO2013160222A1 (ru)
ZA (1) ZA201407345B (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111821299A (zh) * 2019-04-16 2020-10-27 天津合美医药科技有限公司 噻吩衍生物用于治疗免疫球蛋白E（IgE）介导的疾病的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006002734A1 (en) * 2004-07-01 2006-01-12 Unilever N.V. Moisture barrier
CA2578384A1 (en) * 2004-09-06 2006-03-16 Altana Pharma Ag Novel pyrazolopyrimidines
US7705014B2 (en) * 2005-04-12 2010-04-27 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
UY30892A1 (es) * 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
SG172926A1 (en) * 2009-01-30 2011-08-29 Glaxosmithkline Llc Crystalline n-{(1-s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
CA2777085A1 (en) * 2009-10-08 2011-04-14 Glaxosmithkline Llc Combination
WO2011146710A1 (en) * 2010-05-21 2011-11-24 Glaxosmithkline Llc Combination

Also Published As

Publication number Publication date
US20150087683A1 (en) 2015-03-26
BR112014026706A2 (pt) 2017-06-27
HK1201726A1 (en) 2015-09-11
IL235159A0 (en) 2014-12-31
CA2873751A1 (en) 2013-10-31
KR20150010943A (ko) 2015-01-29
AR090795A1 (es) 2014-12-10
WO2013160222A1 (en) 2013-10-31
AU2013254849A1 (en) 2014-11-06
PE20142356A1 (es) 2015-01-30
EP2841053A1 (en) 2015-03-04
JP2015514792A (ja) 2015-05-21
MX2014012904A (es) 2014-11-21
NZ628394A (en) 2016-02-26
UA113875C2 (uk) 2017-03-27
CO7111283A2 (es) 2014-11-10
PH12014502400A1 (en) 2015-01-12
CN104302275A (zh) 2015-01-21
UY34762A (es) 2013-11-29
TW201347758A (zh) 2013-12-01
ZA201407345B (en) 2015-11-25
CR20140491A (es) 2014-12-22
AU2013254849B2 (en) 2016-05-26
CL2014002861A1 (es) 2015-01-16
DOP2014000238A (es) 2014-12-15
SG11201406409VA (en) 2014-11-27
US20160143885A1 (en) 2016-05-26

Similar Documents

Publication Publication Date Title
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
EA201491933A1 (ru) Дигидрат соединения бензотиофена или его соли и способ его получения
EA201591296A1 (ru) Фталазиноны и изохинолиноны в качестве ингибиторов rock
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
EA201692166A1 (ru) Гетероциклические ингибиторы глютаминазы
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
EA201690962A1 (ru) Составы
RU2012140185A (ru) Ингибирование ангиогенеза
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
EA201400245A1 (ru) Ингибиторы dyrk1 и их применение
EA201490650A1 (ru) Фармацевтические композиции
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
EA201690386A1 (ru) Соединения и композиции в качестве ингибиторов mek
EA201300131A1 (ru) Комбинированная фармацевтическая композиция и методы лечения заболеваний или состояний, связанных с респираторными заболеваниями или состояниями
MX2017005861A (es) Metodos para el control transcripcional objetivo en regiones del super mejorador.
EA201400623A1 (ru) Новые 2h-индазолы в качестве антагонистов рецептора ep
BR112016029012A2 (pt) método de tratamento de câncer de pulmão de células não pequenas e/ou câncer de pulmão de células pequenas usando compostos de tienotriazolodiazepina
EA201391027A1 (ru) Комбинация
MX357763B (es) Tratamiento para cancer pancreatico.
EA201490516A1 (ru) Бифенилкарбоксиамиды в качестве ингибиторов rock-киназ
EA201792264A1 (ru) Способы лечения воспалительных заболеваний
EA201691299A1 (ru) Применение лахинимода для замедления прогрессирования болезни хантингтона
EA201491982A1 (ru) Антибактериальные хинолиновые производные
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний